Medivo to Introduce the Results of Using Clinical Diagnostics Based Artificial Intelligence to Predict Disease
Medivo to Introduce the Results of Using Clinical Diagnostics Based Artificial Intelligence to Predict Disease
Presentation at PharmaForce Conference Demonstrates How Pharma Brands Can Leverage Clinical Data, Analytics, and AI to Identify the Right Patients Earlier and Drive Decisions That Will Improve Patient Health.
PR Newswire
NEW YORK, Sept. 13, 2016
NEW YORK, Sept. 13, 2016 /PRNewswire/ -- Medivo, Inc., a leader in clinical diagnostic analytics, will host a roundtable session as well as address the entire audience at the PharmaForce Annual Conference, which is being held September 12-14, 2016 at The Westin Princeton at Forrestal Village in Princeton, New Jersey.
The sessions will be led by Jason Bhan, MD, Medivo's Chief Medical Officer and Co-Founder, and focus on the importance of clinical diagnostics in reacting to the opportunities and challenges facing pharma brands and drugs in the pipeline, and the value of clinical diagnostics in precision medicine. Dr. Bhan will explore challenges related to the latest evolutions in the pharma commercial market, such as increasing healthcare costs, new commercial models, and small markets.
Medivo's CLEAR Insights allow brand marketers to develop intelligent physician profiling and early insights based on data from Medivo's nationwide network of partner labs, which offers access to over 150 million patients. Lab data is critical as it influences 70% or more of medical decisions and can be delivered within a few days of testing, making it available well before the treatment decisions are made.
"Clinical diagnostics data provides insights that other data sources cannot," said Dr. Bhan. "As a physician, this information is invaluable in choosing the best course of treatment for a patient. The same is true for pharma brands in recommending their therapies."
"Medivo's clinical diagnostic solutions provide fast and actionable insights that allow Life Science Brand marketers to find the right patients based on specific biomarkers," adds Anne Bentley, Chief Marketing Officer at Medivo. "Because our solutions allow pharma brands to influence treatment decisions before they are made, they contribute immensely to brand success."
Medivo will exhibit at the PharmaForce conference at booth #2, and will host their keynote address and roundtable sessions entitled "Addressing Pharma Brand Challenges with Clinical Diagnostics" on Tuesday, September 13th. Attendees hoping to connect with Medivo at the conference can submit their contact information at the following web address: http://info.medivo.com/pharmaforce2016.
About Medivo
Medivo is a healthcare analytics company that unlocks the power of clinical diagnostic data to improve health. Medivo is the largest source of clinical diagnostic data in the U.S., with access to over 150 million patients and 4 billion lab records through its nationwide network of partner labs. Medivo has over six years experience in developing proprietary clinical algorithms and deploying advanced analytics solutions for healthcare companies to improve targeting, commercial effectiveness, quality improvement and risk management. Founded in 2010, Medivo's investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.
Logo - http://photos.prnewswire.com/prnh/20151102/282959LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medivo-to-introduce-the-results-of-using-clinical-diagnostics-based-artificial-intelligence-to-predict-disease-300327069.html
SOURCE Medivo, Inc.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.